-
Mashup Score: 14Jean-Yves Blay | ESMO - 1 month(s) ago
His research interests focus on clinical and basic research in sarcomas, targeted treatment of cancer, the biology of breast carcinoma…
Source: www.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 28Carmen Criscitiello - 2 month(s) ago
Carmen Criscitiello is a scientist and senior physician appointed with High Specialty in Immunotherapy at the Division of Early Drug Development…
Source: www.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
The HER2DX risk-score has undergone rigorous validation in prior investigations involving patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer. In this study, we present the outcomes of the HER2DX risk-score within the most recent release of the Sweden Cancerome Analysis Network—Breast (SCAN-B) HER2+ cohort. This updated examination benefits from a larger patient sample, an extended follow-up duration, and detailed treatment information.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
📰 Hot off the press: among 757 patients with early HER2+ breast cancer in the Swedish SCAN-B cohort, the HER2DX risk-score as a continuous variable was found significantly associated with OS after adjustment for clinical variables and treatment regimen. https://t.co/tubg5vWo7L https://t.co/sGpnCxMDof
-
-
Mashup Score: 40Evandro de Azambuja | ESMO - 2 month(s) ago
Evandro de Azambuja, MD, PhD, is the Head of the Medical Support Team (Academic Promoting Team) located at the Jules Bordet Institute in Brussels
Source: www.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet-
Our Editor Spotlight this week is Evandro de Azambuja, MD, PhD (@E_de_Azambuja), Ass. Editor for ESMO guidelines @ESMO_Open. Dr. de Azambuja focuses his research on cardiotoxicity & on the development of new drugs to prevent recurrence from breast cancer. https://t.co/ek1GPh6cxW. https://t.co/sJGE6cYsN1
-
-
Mashup Score: 4
Our Editor Spotlight this week is Chiara Cremolini – ESMO Open / biomarker discovery, cancer, Chiara Cremolini, clinical research, ESMO, ESMO Open, GI tumors,
Source: oncodaily.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 26Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing - 2 month(s) ago
The FUTURE trial (UMIN000029294) demonstrated the safety and efficacy of adding palbociclib after fulvestrant resistance in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced and metastatic breast cancer (ABC/MBC). In this planned sub-study, cancer panel sequencing of cell-free DNA (cfDNA) was utilized to explore prognostic and predictive biomarkers for further palbociclib treatment following fulvestrant resistance.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17Andres Cervantes - 2 month(s) ago
Dr. Cervantes serves as Head of the Department of Medical Oncology at the University Hospital in Valencia, Spain.
Source: www.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet-
Our Editor Spotlight this week is Andrés Cervantes, MD, PhD (@AndresC27622123), @myESMO President & Ass. Editor for Early Drug Development @ESMO_Open. Prof. Cervantes focuses his research on new drugs and biomarkers for rectal cancer and other GI tumors. https://t.co/2KtdmOWE4a https://t.co/8oRbzHGUqg
-
-
Mashup Score: 61Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes - 3 month(s) ago
Sexual concerns are a major unaddressed need among survivors of breast cancer (BC) with significant negative effects on quality of life. We longitudinally analyzed sexual health over time, using patient-reported outcomes.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
What is the incidence of sexual health concerns among patients diagnosed with breast cancer? In a large (n=7985) longitudinal cohort from 26 French centers, @AliceFranzoi et al report 78% incidence of any sexual concern, with <50% receiving proper support. https://t.co/bKjBGw6go6 https://t.co/qsXBnz4oEK
-
-
Mashup Score: 57Toni Choueiri, MD - Dana-Farber Cancer Institute | Boston, MA - 3 month(s) ago
Toni Choueiri, MD – Medical Oncology
Source: www.dana-farber.orgCategories: General Medicine News, Onc News and JournalsTweet-
Our Editor Spotlight this week is Toni Choueiri, MD (@DrChoueiri), Chief @DanaFarber_GU, Prof. @Harvard and Associate Editor @ESMO_Open. Dr. Choueiri focuses his research on the development of novel drugs and biomarkers for RCC and other GU malignancies. https://t.co/XoR5Y9M4Jh https://t.co/2cqt6XpMvT
-
-
Mashup Score: 61Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy? - 3 month(s) ago
Controlled ovarian stimulation (COS) for oocyte/embryo cryopreservation is the method of choice for fertility preservation (FP) in young patients diagnosed with early-stage breast cancer (eBC). Nevertheless, some challenges still question its role, particularly in the neoadjuvant setting, where concerns arise about potential delay in the onset of anticancer treatment, and in hormone receptor-positive (HR+) disease, as cancer cells may proliferate under the estrogenic peak associated with stimulation.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet
Our Editor Spotlight this week is Jean-Yves Blay, MD, PhD (@jeanyvesblay), @ESMO_Open Editor for Sarcoma. Dr. Blay’s work focuses on genomics and targeted treatment of cancer, immune-oncology, and the improvement in quality of care of patients with cancer. https://t.co/Vip9yoI2BA https://t.co/JNjgKBZSpX